22:04 , Jul 19, 2018 |  BC Innovations  |  Tools & Techniques

Immunotherapy Matchmaking

MD Anderson Cancer Center is using its access to patient samples to inject more rationality into decisions about which therapies should be paired with checkpoint inhibitors, and how to optimize the combos. The goal is...
18:33 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Tricida, Translate Bio, Forty Seven and Entera price IPOs

Among three well-funded biotechs that priced IPOs, Tricida Inc. (NASDAQ:TCDA) had by far the best first-day performance on June 28, posting a 37% gain, while Translate Bio Inc. (NASDAQ:TBIO) and Forty Seven Inc. (NASDAQ:FTSV) each...
05:15 , Jun 28, 2018 |  BC Extra  |  Financial News

Tricida gains, others dip after upsized IPOs

Among three well-funded biotechs that priced IPOs, Tricida Inc. (NASDAQ:TCDA) had by far the best first-day performance Thursday, posting a 37% gain, while Translate Bio Inc. (NASDAQ:TBIO) and Forty Seven Inc. (NASDAQ:FTSV) each lost ground. All...
00:25 , Jun 16, 2018 |  BioCentury  |  Product Development

NSCLC disrupted

This year’s ASCO made clear that PD-1 inhibitors have supplanted chemotherapy as standard of care in first-line metastatic NSCLC. The unanticipated consequence is the knock-on effects for companies with studies under way in both first-...
05:50 , Jun 2, 2018 |  BioCentury  |  Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
19:11 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Vaximm reports final Phase I data for VXM01 in recurrent glioblastoma

Vaximm AG (Basel, Switzerland) reported final data from 14 patients with recurrent glioblastoma in a Phase I trial showing that oral VXM01 on days 1, 3, 5 and 7 led to one durable objective response...
19:10 , May 18, 2018 |  BC Week In Review  |  Clinical News

Merck, Pfizer report early data for PD-L1/ALK inhibitor combos

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) reported data from the Phase Ib/II JAVELIN Lung 101 trial evaluating the partners' PD-L1 inhibitor Bavencio avelumab in combination with Pfizer's anaplastic lymphoma kinase (ALK) inhibitors to treat...
23:54 , May 16, 2018 |  BC Extra  |  Clinical News

Merck, Pfizer report early data for PD-L1/ALK inhibitor combos

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) reported data from the Phase Ib/II JAVELIN Lung 101 trial evaluating the partners' PD-L1 inhibitor Bavencio avelumab in combination with Pfizer's anaplastic lymphoma kinase inhibitors to treat previously...
21:53 , Apr 13, 2018 |  BioCentury  |  Strategy

Self-driving CARs

Novartis AG, Gilead Sciences Inc. and now Pfizer Inc. have taken different approaches to managing their CAR T cell assets, but the three companies appear to be converging on the notion that developing the technology...
21:37 , Feb 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer; melanoma Mouse studies suggest TGFβ-RII-checkpoint inhibitor mAb fusion proteins could help treat checkpoint inhibitor-resistant melanoma and breast cancers. The proteins consist of the TGFβ-RII ectodomain linked to mAbs targeting either CTLA-4 or PD-L1....